FindTrial
Sign In

PD-1/PD-L1 Inhibitors Treatment in Refractory /Relapse EBV-Associated Lymphoproliferative Disease: a Restrospective Study

Restrospective Study for the Effect and Mechanism of PD-1/PD-L1 Inhibitors Treatment in Refractory /Relapse EBV-Associated Lymphoproliferative Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026232
Enrollment
Unknown
Registered
2019-09-28
Start date
2019-09-28
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EBV-associated Lymphoproliferative Disease

Interventions

Case Series:N/A

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients were older than 14 years of age. 2. Confirmed EBV-associated lymphoproliferative disorders treated in West China Hospital between Jan 1st 2018 to 31st Dec 2018. 3. Received one or more injections of PD-1/PD-L1 inhibitors for treatment.

Exclusion criteria

Exclusion criteria: 1. Confirmed autoimmune disease. 2. Post-transplatation.

Design outcomes

Primary

MeasureTime frame
Clinical Response Rate;Change of Plasma EBV-DNA;irAEs;—

Secondary

MeasureTime frame
Overall Survival;Epidemiology Characteristics of EBV-LPDs;Change of Immune Subsets;—

Countries

China

Contacts

Public ContactTing Liu

West China Hospital, Sichuan University

liuting@scu.edu.cn+86 18980601240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026